1.2 TNF-α as an Inflammatory Driver Upon activation, TNF-α triggers a cytokine cascade —a molecular domino effect that mobilizes other immune mediators such as IL-1, IL-6, and interferons.

Discover how moringa oleifera, a nutrient-packed tree, is reshaping modern medicine with its ability to fight inflammation, ...

MYMD-1, a next generation, oral selective inhibitor of tumor necrosis factor-alpha (TNF-α), a driver of chronic inflammation, is being studied to slow the aging process, prevent sarcopenia and ...

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

MYMD-1 is an oral, next-generation TNF-α inhibitor with the potential to transform the way TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier.

“Although the recommendations on which treatment to choose after anti–TNF-α failure are scarce, our findings reflect a pattern in the last 10 years, with greater incorporation of new targets ...

Tumor necrosis factor-alpha (TNF-α) is critically involved in the pathogenesis of several chronic inflammatory diseases. Monoclonal antibodies against TNF-α are currently used for the treatment ...

TNF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has achieved ...

A new study by researchers from National Taiwan University and National Yang Ming Chiao Tung University has identified a promising compound hidden within Antrodia cinnamomea—a medicinal fungus unique ...